Showing results (911-920 of 1,120) with videos related to

Sort By:
Pageof 112
Nature Reviews. Cardiology|March 11, 2026
Antiphospholipid antibodies and cardiovascular thrombosisSina Rashedi, Hannah Leyva, Saman A Siddiqui, et al.
Neuroepidemiology|August 28, 2025
Polypill and RiskOMeter to Prevent StrOke and CogniTive ImpairmEnt in Primary Health Care (PROMOTE) Randomized Clinical Trial: Rationale and DesignMichael Brainin, Craig S Anderson, Philip M Bath, et al.
The New England Journal of Medicine|November 12, 2023
Apixaban for Stroke Prevention in Subclinical Atrial FibrillationJeff S Healey, Renato D Lopes, Christopher B Granger, et al.
Iscience|June 15, 2026
Circulating cell populations as response predictors and targets to improve immunotherapy in metastatic lung cancerAmanda B Figueiredo, Guilherme F B Evangelista, Stephanie M I Ferreira, et al.
American Heart Journal|June 19, 2026
Registry of Atrial Fibrillation in Latin America: Primary Results of the LACROSS StudyPedro Gabriel Melo de Barros E Silva, Lucas Damiani, Paola Engelmann Arantes, et al.
Hypertension (Dallas, Tex. : 1979)|August 28, 2025
Overcoming Barriers to Developing and Implementing Novel Therapies for HypertensionKonstantin A Krychtiuk, Renato D Lopes, Victoria A Cargill, et al.
The New England Journal of Medicine|April 8, 2024
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial InfarctionC Michael Gibson, Danielle Duffy, Serge Korjian, et al.
American Heart Journal|February 12, 2022
Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trialMandeep S Sidhu, Karen P Alexander, Zhen Huang, et al.
Journal of Cardiac Failure|August 30, 2023
In-Hospital Management and Long-term Clinical Outcomes and Adherence in Patients With Acute Decompensated Heart Failure: Primary Results of the First Brazilian Registry of Heart Failure (BREATHE)Denilson Campos DE Albuquerque, Pedro Gabriel Melo DE Barros E Silva, Renato D Lopes, et al.
The Lancet. Diabetes & Endocrinology|September 9, 2024
Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trialMikhail N Kosiborod, Sheryl L Windsor, Orly Vardeny, et al.
Pageof 112